Fragmento

Infection with hepatitis C virus (HCV) genotype (G)5 or G6 is relatively uncommon worldwide, with data on the efficacy of peginterferon/ribavirin (PegIFN/RBV) treatment limited, and sometimes contradictory compared with other HCV genotypes. G5 is predominantly found in South Africa, with local clusters reported in France, Spain, Syria, Belgium and Canada, while G6 has been reported in Asian countries and patients of Asian origin in the US and Canada. Here, we report data from the 25 G5 and G6 patients from the “real world” PROPHESYS study receiving PegIFN alfa-2a (40KD) (PEGASYS®, Roche, Basel, Switzerland) plus RBV. Prophesys was a prospective, non-interventional study of chronic HCV patients receiving treatment according to country-specific requirements, comprising three cohorts of patients enrolled in 19 countries The primary analysis population (N = 7,163) included treatment-naive HCV mono-infected patients who received ≥ 1 dose of PegIFN/RBV, with baseline HCV RNA ≥ 50 IU/mL and ≥1 post-baseline HCV RNA test result.

Palabras clave:

2014-02-28   |   433 visitas   |   Evalua este artículo 0 valoraciones

Vol. 13 Núm.2. Marzo-Abril 2014 Pags. 303-304 Ann Hepatol 2014; 13(2)